Skip to main content

Advertisement

Table 4 Base-case cost-effectiveness results (per patient): discounted lifetime costs, QALYs and incremental cost-effectiveness ratios of BOC/RGT vs. PR48 and BOC/PR48 vs. PR48

From: Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study

  PR48 BOC/RGT BOC/PR48
Costs (2010 US$):    
  AV Therapy Drug Costs 29,573 47,582 69,928
  EPO for treatment-related anemia 3,637 5,050 8,493
  Monitoring Costs 2,110 1,796 2,380
  SVR 0 0 0
  F0-F3 7,538 4,786 4,461
  Compensated Cirrhosis, F4 3,749 2,266 2,100
  Decompensated Cirrhosis 4,223 2,677 2,505
  Hepatocellular Carcinoma 5,043 3,128 2,915
  Liver Transplantation 1,067 669 624
  Post-Liver Transplant 1,822 1,155 1,081
Total Costs 58,761 69,110 94,488
Total QALYs 14.55 15.17 15.20
ICER   16,792/QALY 55,162/QALY
  1. AV therapy – antiviral therapy; SVR – sustained virologic response; F0 – no fibrosis; F1 – portal fibrosis without septa; F2 – portal fibrosis with few septa; F3 – numerous septa without cirrhosis; F4 – cirrhosis; QALY – quality-adjusted life years; ICER – incremental cost-effectiveness ratios; PR48 – peginterferon-ribavirin regimen for 48 weeks; BOC/RGT – peginterferon–ribavirin for 4 weeks followed by peginterferon-ribavirin and boceprevir for 24 weeks, and those with a detectable hepatitis C virus (HCV) RNA level between weeks 8 and 24 received peginterferon–ribavirin from week 28 to week 48; BOC/PR48 –peginterferon–ribavirin for 48 weeks and boceprevir for 44 weeks.